? This K01 award will support the Principal Investigator's development as an independent research scientist conducting economic evaluations of the medical complications of injection drug use (IDU). A team of mentors and advisors with expertise in cost-effectiveness evaluation, epidemiology of drug abuse, hepatitis C clinical treatment, infectious disease modeling, and health behavior research will provide the PI with the necessary support and guidance. The purpose of the research proposal is to determine chronic hepatitis C (HCV) treatment preferences among HCV-infected IDUs and to assess the cost-effectiveness of HCV treatment for 3 specific IDU populations: (1) HCV-infected IDUs in methadone maintenance treatment (MMT) and other substance abuse treatment settings; (2) IDUs co-infected with HIV and HCV who have early stage liver disease; and (3) HCV-infected pregnant women with a history of IDU. An estimated 65 to 90% of injection IDUs are infected with HCV and are at risk for sequelae such as cirrhosis, decompensated liver disease, and hepato-cellular carcinoma. Decisions about HCV treatment require complex trade-offs between uncertain benefits and considerable quality-of-life and financial costs. Combination therapy with ribavirin and pegylated interferon is effective in 40-80% of patients, depending on their genotype, but is costly and potentially toxic. Treatment preferences will be assessed by computer-assisted interviews with 200 HCV-infected patients at 3 New York City hospitals before and after treatment. Cost-effectiveness analysis provides a methodology for analyses to inform HCV treatment resource allocation decisions. Computer simulation models to measure cost effectiveness will be developed using the treatment preferences identified, reports from the literature, results of a survey of MMT providers, and data from HIV/HCV co-infected cohorts in 2 urban clinics.
The specific aims are: (1) To assess preferences and perceived barriers to HCV treatment among HCV patients infected by IDU, and to compare preferences before and after HCV treatment; (2) To conduct a cost-effectiveness analysis of treating IDUs with chronic HCV in MMT clinics and other substance abuse treatment settings, and to determine the budgetary costs of these alternatives for government-funded programs such as Medicaid; (3) To conduct a cost-effectiveness analysis of treating chronic HCV in HIV/HCV co-infected patients with persistently normal or moderately elevated ALT levels and/or stage 1 or 2 liver disease, using cohort data from 2 urban clinics; and (4) To conduct a cost-effectiveness analysis of elective Cesarean delivery for HCV-infected women identified with detectable HCV RNA during pregnancy and of HCV RNA screening of pregnant women with a history of IDU. This work will provide insight into important policy questions identified by the NIH Consensus Development Conference on the Management of Hepatitis C in June 2002 and will inform development of treatment and reimbursement guidelines. ? ? ? ?

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Research Scientist Development Award - Research & Training (K01)
Project #
5K01DA017179-03
Application #
7052786
Study Section
Human Development Research Subcommittee (NIDA)
Program Officer
Duffy, Sarah Q
Project Start
2004-04-01
Project End
2009-03-31
Budget Start
2006-04-01
Budget End
2007-03-31
Support Year
3
Fiscal Year
2006
Total Cost
$178,091
Indirect Cost
Name
Weill Medical College of Cornell University
Department
Public Health & Prev Medicine
Type
Schools of Medicine
DUNS #
060217502
City
New York
State
NY
Country
United States
Zip Code
10065
Novitsky, Vlad; Wang, Rui; Rossenkhan, Raabya et al. (2013) Intra-host evolutionary rates in HIV-1C env and gag during primary infection. Infect Genet Evol 19:361-8
Linas, B P; Wang, B; Smurzynski, M et al. (2011) The impact of HIV/HCV co-infection on health care utilization and disability: results of the ACTG Longitudinal Linked Randomized Trials (ALLRT) Cohort. J Viral Hepat 18:506-12
Bender, Melissa A; Kumarasamy, Nagalingeswaran; Mayer, Kenneth H et al. (2010) Cost-effectiveness of tenofovir as first-line antiretroviral therapy in India. Clin Infect Dis 50:416-25
Christopoulos, Katerina A; Schackman, Bruce R; Lee, Gunjeong et al. (2010) Results from a New York City emergency department rapid HIV testing program. J Acquir Immune Defic Syndr 53:420-2
Paltiel, A David; Freedberg, Kenneth A; Scott, Callie A et al. (2009) HIV preexposure prophylaxis in the United States: impact on lifetime infection risk, clinical outcomes, and cost-effectiveness. Clin Infect Dis 48:806-15
Losina, Elena; Schackman, Bruce R; Sadownik, Sara N et al. (2009) Racial and sex disparities in life expectancy losses among HIV-infected persons in the united states: impact of risk behavior, late initiation, and early discontinuation of antiretroviral therapy. Clin Infect Dis 49:1570-8
Ribaudo, Heather J; Kuritzkes, Daniel R; Lalama, Christina M et al. (2008) Efavirenz-based regimens in treatment-naive patients with a range of pretreatment HIV-1 RNA levels and CD4 cell counts. J Infect Dis 197:1006-10
Schackman, Bruce R; Scott, Callie A; Walensky, Rochelle P et al. (2008) The cost-effectiveness of HLA-B*5701 genetic screening to guide initial antiretroviral therapy for HIV. AIDS 22:2025-33
Schackman, Bruce R; Teixeira, Paul A; Weitzman, Gil et al. (2008) Quality-of-life tradeoffs for hepatitis C treatment: do patients and providers agree? Med Decis Making 28:233-42
Teixeira, Paul A; Schackman, Bruce R (2008) Can urban methadone patients complete health utility assessments? Patient Educ Couns 71:302-7

Showing the most recent 10 out of 20 publications